T2DM Focused Update: SGLT2 Inhibitors & GLP1 Agonists
|Personalized education in 30-60 minutes either in-person visit or web conferencing (e.g., Zoom or WebEx) at a time that is convenient for you. This Group Learning program has been certified by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits.|
Participants will be able to thoughtfully discuss, prescribe and monitor the SGLT2 inhibitors and GLP1 agonists for people with type 2 diabetes.
During each academic detailing session, participants will have the opportunity to:
- Discuss changes to available evidence and clinical practice guidelines which inform medication choices beyond HbA1c lowering.
- Review clinical considerations which support treatment decisions including: doses, adverse events, dosage forms, cost and coverage.
- Specifically discuss the three most commonly prescribed in British Columbia: empagliflozin, semaglutide subcutaneous, canagliflozin.
After the academic detailing session, participants will be able to:
- Consider how changes to the available evidence inform medication choices for cardiovascular, kidney and mortality outcomes.
- Identify the clinical outcomes where confident medication choices cannot yet be made.
- Apply evidence from longer term clinical trials and observational studies which inform dosing and monitoring for adverse events.
When: Until October 13, 2022
Where: In-person at your place of work or virtual academic detailing
How: Contact your local PAD pharmacist directly or email PAD@gov.bc.ca
For more information about the PAD service, visit PAD Frequently Asked Questions.